U.S. and E.U. cardiologists call for a hard check on global sales of renal denervation technology in the wake of Medtronic's disappointing SYMPLICITY HTN-3 study.
MASSDEVICE ON CALL — A group of cardiologists is taking a hard stance against renal denervation, calling for medical device manufacturers to stop selling the technology as a treatment for hypertension.
More results from Medtronic's hypertension studies continue to muddle the outlook for renal denervation as medtech titans vie for prime listing for their transcatheter valves.
The American College of Cardiology's annual Scientific Sessions are regularly a source of controversy and competition, but medtech titan Medtronic's (NYSE:MDT) highly anticipated renal denervation study results may have been the most confounding.
Medtronic's Symplicity renal denervation device for hypertension lowered blood pressure only slightly more than patients treated with drugs and a sham procedure, the company said today at the American College of Cardiology's annual conference.
Medtronic (NYSE:MDT) revealed the details today of a clinical trial of its Symplicity renal denervation treatment for hypertension, but said it still plans to investigate the treatment even though the study showed only meager improvements in high blood pressure compared with a sham procedure.
Johnson & Johnson subsidiary Cordis Corp. wins European CE Mark approval for its Renlane renal denervation system for treating patients with resistant hypertension.
NxStage Medical campaigns to increase awareness of home hemodialysis with the NxStage System One.
NxStage Medical (NSDQ:NXTM) launched a new patient outreach program called NxStage Plus One, through which it hopes to increase awareness of home hemodialysis with the NxStage System One.
The recent chill in renal denervation hasn't slowed down ReCor Medical, which plans to charge forward with its ultrasound-based Paradise system for treatment of hypertension.
Analysts warn that medtech companies may become increasingly cautious toward "risky" bets after Medtronic's near billion-dollar gamble on renal denervation was derailed by a flopped clinical trial.
MASSDEVICE ON CALL — Medtech titan Medtronic (NYSE:MDT) took a risk when it bet nearly $1 billion on renal denervation pioneer Ardian years before its flagship device was slated to hit the U.S. market, and the recent foofaraw over the company's missed clinical trial may have a cooling effect on other device companies, analysts warned.